S S Burtles

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

P. Vasey, Stan B. Kaye, Rachel Morrison et al. · PubMed · 1999 · 691 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin

Leonard W. Seymour, David Ferry, David Anderson et al. · Journal of Clinical Oncology · 2002 · 284 citations

Pharmacy, Oncology, Pharmacology +16

Primary and secondary human in vitro T-cell responses to soluble antigens are mediated by subsets bearing different CD45 isoforms.

Magdalena Plebanski, Margaret Saunders, S S Burtles et al. · PubMed · 1992 · 70 citations · Full text

Life Sciences, Immunology, Microbiology +17

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics

David R. Newell, S S Burtles, B.W. Fox et al. · British Journal of Cancer · 1999 · 67 citations · Full text

Medicine, Pharmacology, Toxicology +12

Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymerdoxorubicin (PK1)

Ruth Duncan, J K Coatsworth, S S Burtles · Human & Experimental Toxicology · 1998 · 66 citations

Pharmacy, Pharmacokinetics, Pharmacology +12